MNPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Monopar Therapeutics Inc (MNPR) does not present a compelling buy opportunity for a beginner, long-term investor at this time. While the company has shown some improvement in financial metrics, the lack of significant positive catalysts, neutral trading sentiment, and absence of strong proprietary trading signals suggest that holding off on investment is prudent.
The MACD histogram is positive and expanding (0.114), indicating a bullish trend. However, the RSI is neutral at 36.742, and moving averages are converging, suggesting no clear direction. The stock is trading near its support level (S1: 52.184), with resistance at R1: 59.969.
Net income improved significantly YoY, up 163.56%.
No recent news or significant trading trends from hedge funds or insiders. Financials show no revenue growth, and the company remains unprofitable with negative EPS (-0.48). No recent congress trading data.
In Q3 2025, the company reported no revenue growth (0% YoY). Net income improved significantly (-$3,437,601, up 163.56% YoY), and EPS improved to -0.48 (up 29.73% YoY). Gross margin remains at 0%.
Morgan Stanley analyst Maxwell Skor initiated coverage with an Overweight rating and a $115 price target, citing promising Phase 3 study results for ALXN1840. This is a positive signal but lacks broad analyst consensus.
